AstraZeneca has agreed to acquire Gracell Biotechnologies, a Chinese developer of cell therapies for the treatment of cancer and autoimmune diseases, for up to $1.2 billion. Only on Dec. 12, 2023, AstraZeneca announced that it was planning to acquire Icosavax for $1.2 billion.
Bristol Myers Squibb will acquire RayzeBio for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired. The transaction was unanimously approved by both the Bristol Myers Squibb and RayzeBio Boards of Directors.
Barentz has acquired Radian in India, reinforcing its product portfolio with color cosmetic ingredients. The move anticipates substantial growth in the Asia Pacific region. Radian's CEO, Manoj Botadra, and the current team will continue to manage operations, ensuring a smooth transition.
Bristol Myers Squibb (BMS) and Karuna Therapeutics have entered into a definitive merger agreement under which the US drug maker has agreed to acquire the Boston-based biopharmaceutical company for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired. The transaction was unanimously approved by both the BMS and Karuna Boards of Directors.
Swiss Biosynth, a supplier of raw materials to the life science industry, has acquired VIO Chemicals, a Zurich, Switzerland-based company with leading chemical R&D expertise and a global network of large-scale manufacturing partners. Financial details of the transaction have not been disclosed.
Dutch fertilizer and industrial chemicals group OCI Global has agreed to sell 100% of its equity interests in its US nitrogen fertilizer facility Iowa Fertilizer Company (IFCO), located in Wever, Iowa, to Koch Ag & Energy Solutions (KAES) for $3.6 billion.
Abu Dhabi National Oil Company (ADNOC) has agreed to acquire OCI Global's entire majority stake in fertilizer producer Fertiglobe for $3.62 billion. Fertiglobe is a joint venture established in October 2019 between the state-owned oil company of the United Arab Emirates (UAE) and the Dutch fertilizer and industrial chemicals group.
Samyang Holdings has acquired the management rights of the U.S.-based specialty chemical manufacturer Verdant Specialty Solutions from private equity firm OpenGate Capital. The total acquisition was approximately €230 million ($250 million).
AstraZeneca has entered into an agreement to acquire Icosavax, a US biopharmaceutical company based in Seattle in a deal worth up to $1.1 billion. The company focuses on the development of differentiated vaccines with high potential using an innovative virus-like protein (VLP) particle platform.
In a move to complement its neuroscience portfolio, US drugmaker AbbVie has agreed to acquire Cerevel Therapeutics, which has a pipeline of multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson's disease (PD), and mood disorders.
In a move to participate in the race for anti-obesity drugs, Swiss pharma giant Roche has agreed to acquire Carmot Therapeutics, a privately owned US company based in Berkeley, California.
In a move to focus on its core businesses, Finnish chemicals company Kemira has signed an agreement to divest its oil and gas-related portfolio for €260 million to Sterling Specialty Chemicals, a US subsidiary of Artek Industries, a global industrial chemicals group based in India.
US fertilizer producer CF Industries has completed the acquisition of the ammonia production complex of Incitec Pivot Limited (IPL) in Waggaman, Louisiana, USA, for $1.675 billion.
On Dec. 1, 2023, French chemicals and materials company Arkema has finalized the acquisition of Glenwood Private Equity’s 54% – based on a €728 million enterprise value – stake in South Korean company PI Advanced Materials (PIAM). Arkema said in a statement that this acquisition acquisition – first announced last June – complements its portfolio of high-performance technologies for the high-growth markets of advanced electronics and electric mobility.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
Olefins and polyolefins producer Borealis has signed an agreement to acquire Integra Plastics, a Bulgarian advanced mechanical recycling company. Closing of the transaction, for which no financial details were disclosed, is subject to customary regulatory approvals.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides.
Merck & Co. (MSD) and Caraway Therapeutics announced that the companies have agreed Merck & Co., through a subsidiary, will acquire Caraway Therapeutics for a total potential consideration of up to €557 million ($610 million), including an undisclosed upfront payment and contingent milestone payments.
Sweden’s Hexpol has acquired the American thermoplastic elastomers (TPE) compounder Star Thermoplastic Alloys and Rubbers for $26.5 million from Thomas A. Dieschbourg, who founded the company in 1993 and will remain as its president.
Azelis has agreed to acquire 100% of the shares of Agspec Australia, a leading distributor of crop nutrition, crop protection and specialty agricultural products in Australia. Financial terms of the transaction, which is expected to close in the first quarter of 2024 and is subject to customary closing conditions, were not disclosed.
Noramco, a US producer of active pharmaceutical ingredients (APIs), has completed the acquisition of the Cambrex drug product business unit previously known as Halo Pharmaceuticals. Financial details were not disclosed.
DKSH has signed an agreement to acquire 100% of Bio-Strategy, said to be the largest independent distributor of scientific instruments in Australia and New Zealand, with a focus primarily on life sciences, medical & healthcare and environment & agriculture.
Anglo-Swedish drugmaker AstraZeneca entered into a collaboration and investment agreement with Cellectis, a French clinical-stage biotechnology company, to accelerate the development of therapeutics across oncology, immunology and rare diseases.
Clariant today announced that it has agreed to acquire Lucas Meyer Cosmetics, a provider of high-value ingredients for the cosmetics and personal care industry, from International Flavors & Fragrances (IFF) for a total cash consideration of €765 million ($810 million).
The US pharmaceutical company Pfizer has been cleared to acquire Seagen, a biotech company focused on developing cancer treatments.
US paints and coatings group PPG has divested all Traffic Solutions operations in Australia and New Zealand to Geveko Markings, a pavement markings specialist headquartered in Sweden. Financial terms of the agreement were not disclosed.
LyondellBasell acquired its 50% share from De Paauw Sustainable Resources (DPSR) CEO Roy de Paauw and ING Corporate Investments. DPSR is a plastics waste recycling company based out of the Netherlands.
Novo Nordisk has agreed to acquire ocedurenone for uncontrolled hypertension with potential application in cardiovascular and kidney disease from KBP Biosciences for up to $1.3 billion.
US specialty chemicals company Albemarle has announced that it will not pursue a binding agreement to purchase Liontown Resources and has formally withdrawn its non-binding offer.
Sterling Pharma Solutions has completed the acquisition of UK-based NewChem Technologies, a contract services provider focused on organic chemistry and supplying customers across a range of industries from pharmaceuticals, diagnostics and biotechnology, to veterinary science and chemicals.
Private equity group SK Capital Partners has agreed to acquire US company J&K Ingredients, currently owned by Core Industrial Partners.
The US energy sector is on the verge of a mega merger: energy and petrochemical giant ExxonMobil has announced its intention to take over producer Pioneer Natural Resources. The merger is planned as an all-stock transaction valued at $59.5 billion, or $253 per share, based on ExxonMobil’s closing price on Oct. 5, 2023, according to a company statement. First reports about the ongoing negotiations already circulated last week.
Bristol-Myers Squibb (BMS) announced that it will acquire Mirati Therapeutics for up to $5.8 billion. BMS is to pay $58.00 per share in cash, for a total equity value of $4.8 billion, diversifying its oncology business and adding drugs it hopes can help offset expected lost revenue from patent expirations later this decade.
Kensing, a manufacturer of natural vitamin E, plant sterols, and high-purity surfactants, announced the acquisition of Advanced Organic Materials (AOM), a producer of non-GMO plant-based vitamin E and phytosterols derived from sunflower and rapeseed.
Eli Lilly announced that it is acquiring radiopharmaceutical company Point Biopharma for $12.50 per share in cash, valuing the deal at approximately $1.4 billion. Point has pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer. The transaction has been approved by the boards of directors of both Indianapolis-based US companies.
